血清IL-23 UCH-L1 miR-424与足月新生儿HIE病情程度的关系及预测预后价值

doi:10.3969/j.issn.1006-6233.2024.12.014

Abstract
Figure/Table
References
Related Citation (10)

Download: PDF (1281 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the relationship of serum interleukin-23 (IL-23), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and micrnas 424 (miR-424) with the severity of hypoxic-ischemic encephalopathy (HIE) in full-term neonates and their predictive value on prognosis.Methods: A total of 105 cases of full-term infants with HIE diagnosed in the period from January 2019 to December 2022 were selected as the HIE group, which were further divided into mild (37 cases), moderate (43 cases), and severe (25 cases) subgroups according to the HIE grading criteria. Additionally, 105 cases of full-term healthy newborns from the same period were selected as the control group. Venous blood samples were collected from all subjects within one day of enrollment, and serum levels of IL-23 and UCH-L1 were measured using enzyme-linked immunosorbent assay (ELISA), while serum miR-424 levels were determined using real-time quantitative polymerase chain reaction (qRT-PCR). The serum levels of IL-23, UCH-L1, and miR-424 were compared between the HIE group and the control group, and the correlation between these markers and the severity of HIE was analyzed. The HIE group was followed up for one year, and according to the prognosis, they were further divided into the good prognosis subgroup and the poor prognosis subgroup. The serum levels of IL-23, UCH-L1, and miR-424 were compared between these two subgroups, and the predictive value of these markers for prognosis was analyzed.Results: The serum levels of IL-23 (68.67±21.29) ng/L and UCH-L1 (1.98±0.63) ng/mL in the HIE group were higher than those in the control group (30.06±6.13) ng/L and (0.75±0.24) ng/mL, respectively. Meanwhile, the serum level of miR-424 (1.98±0.63) was lower than that in the control group (1.02±0.11) (P<0.05). In the severe HIE subgroup, the serum levels of IL-23 (95.21±21.08) ng/L and UCH-L1 (2.42±0.46) ng/mL were higher than those in the moderate HIE subgroup (70.49±18.13) ng/L and (2.01±0.40) ng/mL, respectively, and those in the mild HIE subgroup (48.62±14.72) ng/L and (1.65±0.34) ng/mL. The moderate HIE subgroup had higher serum levels of IL-23 and UCH-L1 than the mild HIE subgroup, while the serum level of miR-424 (0.53±0.10) was lower than that in the moderate HIE subgroup (0.70±0.12) and mild HIE subgroup (0.84±0.16), with the moderate HIE subgroup having lower serum levels of miR-424 than the mild HIE subgroup (P<0.05). Serum levels of IL-23 and UCH-L1 positively correlate with the severity of the disease, while miR-424 levels negatively correlate with it (P<0.05). After a 1-year follow-up, 1 case was lost. Among the 104 children, 82 had a good prognosis and 22 had a poor prognosis. The poor prognosis subgroup had lower Apgar scores at 1 and 5 minutes, as well as lower NBNA scores, and a higher severity of illness compared to the good prognosis subgroup (P<0.05). The serum levels of IL-23 (94.41±20.35) ng/L and UCH-L1 (2.46±0.62) ng/mL in the poor prognosis subgroup were higher than those in the good prognosis subgroup (61.76±18.74) ng/L and (1.84±0.49) ng/mL, respectively, while miR-424 levels (0.51±0.16) were lower than those in the good prognosis subgroup (0.75±0.20) (P<0.05). Partial correlation analysis showed that, after controlling for other factors, serum levels of IL-23, UCH-L1, and miR-424 were significantly associated with the prognosis of full-term HIE patients (P<0.05). The AUCs for predicting the prognosis of full-term HIE patients using serum levels of IL-23, UCH-L1, and miR-424 were 0.815, 0.792, and 0.806, respectively. The AUC for combined prediction was 0.913, with a sensitivity of 81.82% and a specificity of 86.59%, which was superior to the predictive value of each individual indicator.Conclusion: Serum IL-23, UCH-L1 and miR-424 are significantly correlated with the severity of full-term neonates with HIE, and have independent prognostic ability, and the combined prognostic value is more reliable.

Key words： Full-term newborn Hypoxic ischemic encephalopathy Interleukin-23 Ubiquitin carboxy-terminal hydrolase -L1 Microrna-424

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2024.12.014 OR http://www.hbyxzzs.cn/EN/Y2024/V30/I12/2017

[1] Ristovska S,Stomnaroska O,Danilovski D.Hypoxic ischemic encephalopathy (HIE) in term and preterm infants[J].Pril (Makedon Akad Nauk Umet Odd Med Nauki),2022,43(1):77-84.
[2] Carreras N,Arnaez J,Valls A,et al.CSF neopterin and beta-2-microglobulin as inflammation biomarkers in newborns with hypoxic-ischemic encephalopathy[J].Pediatr Res,2023,93(5):1328-1335.
[3] Hu Y,Qi CY,Shi JY,et al.Podocyte-specific deletion of ubiquitin carboxyl-terminal hydrolase L1 causes podocyte injury by inducing endoplasmic reticulum stress[J].Cell Mol Life Sci,2023,80(4):106.
[4] Cao YX,Wang ZQ,Kang JX,et al.miR-424 protects PC-12 cells from OGD-induced injury by negatively regulating MKP-1[J].Eur Rev Med Pharmacol Sci,2018,22(5):1426-1436.
[5] 中华医学会儿科学分会新生儿学组.新生儿缺氧缺血性脑病诊断标准[J].中华儿科杂志,2005,43(8):584-584.
[6] 韩玉昆.新生儿缺氧缺血性脑病[M].第2版.北京:人民卫生出版社,2010.11-12.
[7] 王永霞,丁学星,李月花.缺氧缺血性脑病新生儿血清MBP HMGB1 IL-23与IL-17的变化及与预后的相关性[J].中国实用神经疾病杂志,2022,25(12):1501-1506.
[8] Higaki A,Mahmoud AUM,Paradis P,et al.Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension[J].Cardiovasc Res,2021,117(5):1274-1283.
[9] Gelderblom M,Gallizioli M,Ludewig P,et al.IL-23 (interleukin-23)-producing conventional dendritic cells control the detrimental IL-17 (interleukin-17) response in stroke[J].Stroke,2018,49(1):155-164.
[10] 丁丽丽,吴宏伟.新生儿缺氧缺血性脑病血清UCH-L1水平变化及临床意义[J].中国妇幼健康研究,2022,33(12):108-113.
[11] Looney AM,O'Sullivan MP,Ahearne CE,et al.Altered expression of umbilical cord blood levels of miR-181b and its downstream target mUCH-L1 in infants with moderate and severe neonatal hypoxic-ischaemic encephalopathy[J].Mol Neurobiol,2019,56(5):3657-3663.
[12] Zeng SY,Huang YB,Zhong T,et al.The expression and clinical value of ubiquitin carboxyl-terminal hydrolase L1 in the blood of neonates with hypoxic ischemic encephalopathy[J].Transl Pediatr,2021,10(8):2063-2068.
[13] Dastmalchi N,Baradaran B,Banan Khojasteh SM,et al.miR-424:a novel potential therapeutic target and prognostic factor in malignancies[J].Cell Biol Int,2021,45(4):720-730.